IL73883A - Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha - Google Patents

Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha

Info

Publication number
IL73883A
IL73883A IL73883A IL7388384A IL73883A IL 73883 A IL73883 A IL 73883A IL 73883 A IL73883 A IL 73883A IL 7388384 A IL7388384 A IL 7388384A IL 73883 A IL73883 A IL 73883A
Authority
IL
Israel
Prior art keywords
alpha
tnf
purification
monoclonal antibodies
antibodies against
Prior art date
Application number
IL73883A
Other languages
English (en)
Other versions
IL73883A0 (en
Inventor
Wallach David
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11055557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL73883(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to IL73883A priority Critical patent/IL73883A/xx
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IL73883A0 publication Critical patent/IL73883A0/xx
Priority to DE198585115918T priority patent/DE186833T1/de
Priority to DE19853586536 priority patent/DE122004000005I1/de
Priority to DE200412000017 priority patent/DE122004000017I1/de
Priority to DE200412000007 priority patent/DE122004000007I1/de
Priority to EP85115918A priority patent/EP0186833B2/de
Priority to DE3586536T priority patent/DE3586536T3/de
Priority to CA000498017A priority patent/CA1337518C/en
Priority to AU51424/85A priority patent/AU601144B2/en
Priority to JP60286811A priority patent/JPS61191620A/ja
Priority to ZA859757A priority patent/ZA859757B/xx
Publication of IL73883A publication Critical patent/IL73883A/xx
Priority to US07/794,365 priority patent/US6090923A/en
Priority to JP5269155A priority patent/JPH0787966A/ja
Priority to NL300142C priority patent/NL300142I2/nl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL73883A 1984-12-20 1984-12-20 Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha IL73883A (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IL73883A IL73883A (en) 1984-12-20 1984-12-20 Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
DE198585115918T DE186833T1 (de) 1984-12-20 1985-12-13 Zytotoxisches protein, verfahren zum isolieren desselben, monoklonaler antikoerper ct-1 und denselben erzeugendes hybridoma.
DE19853586536 DE122004000005I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antik¦rper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren f}r die Herstellung des gereinigten Cytotoxin
DE200412000017 DE122004000017I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antik¦rper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren f}r die Herstellung des gereinigten Cytotoxin.
DE200412000007 DE122004000007I1 (de) 1984-12-20 1985-12-13 Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin.
EP85115918A EP0186833B2 (de) 1984-12-20 1985-12-13 Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin
DE3586536T DE3586536T3 (de) 1984-12-20 1985-12-13 Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin.
CA000498017A CA1337518C (en) 1984-12-20 1985-12-18 Monoclonal antibodies against tnf-–, hybridomas producing them and method for the purification of tnf-–
AU51424/85A AU601144B2 (en) 1984-12-20 1985-12-18 Cytotoxic protein
JP60286811A JPS61191620A (ja) 1984-12-20 1985-12-19 細胞毒素及びその応用
ZA859757A ZA859757B (en) 1984-12-20 1985-12-20 A cytotoxic protein
US07/794,365 US6090923A (en) 1984-12-20 1991-11-13 Murine monoclonal antibody binding TNFα
JP5269155A JPH0787966A (ja) 1984-12-20 1993-10-27 細胞毒素及びその応用
NL300142C NL300142I2 (nl) 1984-12-20 2004-02-12 Monoclonaal antilichaam tegen een cytotoxine, hybridoma cellijn, die dat uitdrukt en werkwijze voor de bereiding van het gezuiverde cytotoxine.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL73883A IL73883A (en) 1984-12-20 1984-12-20 Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha

Publications (2)

Publication Number Publication Date
IL73883A0 IL73883A0 (en) 1985-03-31
IL73883A true IL73883A (en) 1990-12-23

Family

ID=11055557

Family Applications (1)

Application Number Title Priority Date Filing Date
IL73883A IL73883A (en) 1984-12-20 1984-12-20 Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha

Country Status (9)

Country Link
US (1) US6090923A (de)
EP (1) EP0186833B2 (de)
JP (2) JPS61191620A (de)
AU (1) AU601144B2 (de)
CA (1) CA1337518C (de)
DE (5) DE122004000005I1 (de)
IL (1) IL73883A (de)
NL (1) NL300142I2 (de)
ZA (1) ZA859757B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019385A (en) * 1984-11-09 1991-05-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Novel lymphopine LK 2 and pharmaceutic compositions containing same
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JP3155961B2 (ja) * 1987-12-30 2001-04-16 煕 中島 抗ビリルビンモノクローナル抗体固定担体およびその製造方法
WO1989009831A1 (en) * 1988-04-15 1989-10-19 Research Corporation Technologies, Inc. Lak cell cytotoxin
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
DE69321909T2 (de) * 1992-08-28 1999-04-01 Bayer Corp., Pittsburgh, Pa. Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden
US7166423B1 (en) 1992-10-21 2007-01-23 Miltenyi Biotec Gmbh Direct selection of cells by secretion product
WO1994009117A1 (en) * 1992-10-21 1994-04-28 Miltenyi Biotec Inc Direct selection of cells by secretion product
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
NZ512006A (en) 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
IL126024A0 (en) * 1998-03-19 1999-05-09 Yeda Res & Dev Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
IL132105A0 (en) * 1998-12-24 2001-03-19 Yeda Res & Dev Caspase-8 interacting proteins
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP2005509647A (ja) * 2001-11-06 2005-04-14 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ エストロゲン応答性乳癌の治療方法
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004019860A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
US20040091490A1 (en) * 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
ES2347239T3 (es) 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
JP4350148B2 (ja) 2004-03-31 2009-10-21 ザ ジェネラル ホスピタル コーポレイション 上皮細胞成長因子受容体ターゲティング治療に対する癌の応答性を決定する方法
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
KR20150006085A (ko) 2006-04-05 2015-01-15 애브비 바이오테크놀로지 리미티드 항체 정제
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
KR101461659B1 (ko) 2007-05-11 2014-11-17 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
KR101563753B1 (ko) 2007-05-11 2015-10-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 피부 궤양의 치료 방법
WO2008149147A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US8399627B2 (en) 2007-12-31 2013-03-19 Bayer Pharma AG Antibodies to TNFα
NZ601913A (en) 2008-01-15 2014-02-28 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
EP2228652A1 (de) 2009-03-11 2010-09-15 Medizinische Universität Wien Verbesserung bei der Tumorbehandlung
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2720721B1 (de) 2011-06-17 2017-08-30 President and Fellows of Harvard College Frizzled 2 als zielmolekül für therapeutische antikörper bei der behandlung von krebs
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3708184A1 (de) 2013-03-27 2020-09-16 The General Hospital Corporation Verfahren und mittel zur behandlung von morbus alzheimer
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR102473092B1 (ko) 2014-09-15 2022-12-01 칠드런'즈 메디컬 센터 코포레이션 히스톤 h3-리신 트리메틸화를 제거함으로써 체세포 핵 이식(scnt) 효율을 증가시키는 방법 및 조성물
JP2023554200A (ja) 2020-12-09 2023-12-26 エイチケー イノ．エヌ コーポレーション 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4843841B1 (de) * 1969-09-06 1973-12-21
GB1541435A (en) * 1975-02-04 1979-02-28 Searle & Co Immunological materials
DE3280462T2 (de) * 1981-09-08 1995-04-20 The Rockefeller University, New York, N.Y. Antikörper gegen eine Zusammensetzung mit Mediatoraktivität und seine Verwendung in einer pharmazeutischen Zusammensetzung.
US5700466A (en) * 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
JPS58138383A (ja) † 1982-02-13 1983-08-17 Nippon Shinyaku Co Ltd 生理活性物質の製法
EP0117705A3 (de) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monocyten und Blastzellen spezifischer monoklonaler Antikörper
JPH0780914B2 (ja) * 1984-04-02 1995-08-30 旭化成工業株式会社 ヒト腫瘍壊死因子に対する抗体
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
GR851626B (de) * 1984-07-05 1985-11-26 Genentech Inc
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
DE122009000074I1 (de) * 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.

Also Published As

Publication number Publication date
EP0186833B2 (de) 2001-11-28
AU601144B2 (en) 1990-09-06
JPS61191620A (ja) 1986-08-26
EP0186833A3 (en) 1987-05-27
JPH0787966A (ja) 1995-04-04
DE3586536T3 (de) 2002-05-08
DE3586536D1 (de) 1992-09-24
DE122004000017I1 (de) 2005-06-16
EP0186833A2 (de) 1986-07-09
NL300142I2 (nl) 2005-08-01
DE122004000005I1 (de) 2006-06-08
US6090923A (en) 2000-07-18
IL73883A0 (en) 1985-03-31
CA1337518C (en) 1995-11-07
DE122004000007I1 (de) 2004-07-01
NL300142I1 (nl) 2004-04-01
DE3586536T2 (de) 1993-02-18
EP0186833B1 (de) 1992-08-19
AU5142485A (en) 1986-06-26
DE186833T1 (de) 1986-12-18
ZA859757B (en) 1986-09-24

Similar Documents

Publication Publication Date Title
IL73883A (en) Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
GB2128630B (en) Method of affinity purification employing monoclonal antibodies
KR920005690B1 (en) Process for the virus-inactivation of immunoglobulin
IL67721A (en) Hybridoma cell lines,their preparation and their use for the production of human monoclonal antibodies
HU896763D0 (en) Process for the preparation of bispecific monoclonal antibody
EP0249007A3 (de) Verfahren zum Selektionieren von Hybridomas
CS8706136A2 (en) Method of hybridomas making for hiv-virus monoclonal antibody production
HUT38391A (en) Process for preparing new monoclonal antibodies against glycoconjugates and for the utilization thereof
EP0133538A3 (en) Process for the purification of polyisocyanates, and the polyisocyanates so purified
EP0198086A4 (de) Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikörpern, deren herstellung und antivirale menschliche monoklonale antikörper.
RO105652B1 (ro) Procedeu de reducere a heterogenitatii anticorpilor monoclonali
DE3175955D1 (en) Process for the deternination of antigens or antibodies
EP0162034A3 (en) Method of isolating monoclonal antibodies from hybridoma cultures
IL62879A (en) Monoclonal antibodies,clones producing them,preparation of such antibodies and clones and cytotoxic and immunoassay using such antibodies
AU530649B2 (en) Method of manufacturing monoclonal antibodies and capable of manufacturing such antibodies
AU7988282A (en) Method of manufacturing monoclonal antibodies and capable of manufacturing such antibodies
GB8422650D0 (en) Monoclonal antibodies
GB2158094B (en) Anti-human igg monoclonal antibody and process for preparing the same
DE3576359D1 (de) Verfahren zur herstellung von tumorspezifische monoklonale antikoerper produzierenden hybridomazellen.
PL238092A1 (en) Method of manufacture of urea
EP0157574A3 (en) Antitetanic antibody producing human-human hybridoma and method of producing the same
EP0185391A3 (en) Method for the purification of the hbc antigen and method for the measurement of hbc antibodies by using said purified hbc antigen
EP0218587A4 (de) Monoklonale antikörper und immunisierung damit.
EP0191846A4 (de) Herstellung monoklonaler anti-idiotyp-antikörper.
GB8426461D0 (en) Monoclonal antibodies

Legal Events

Date Code Title Description
KB Patent renewed
EXTP Application for extension order is pending
PEL Intention of commissioner to extend period of protection
EXTG Extension of patent term granted
EXTN Extension order renewed
EXTN Extension order renewed
EXP Patent expired